Addex Shareholders Approve All Resolutions at Annual General Meeting

Geneva, Switzerland, 10 June 2020 a?? Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors at its 2020 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 2, no shareholders attended the AGM in person. The voting proxy represented 35.30% of the company's shares.Addex shareholders approved the 2019 annual report, the 2019 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote). All motions regarding the compensation of the board of directors and the executive management were also approved. In addition, discharge was granted to the members of the board of directors and the executive management for their activities during the business year 2019. Addex shareholders approved Addex Therapeuticsa?? Equity Incentive Plan, following the listing of American Depository Shares (a??ADSa??) representing Addex Therapeuticsa?? shares on the United States NASDAQ stock exchange.Addex shareholders also approved the amendment of the articles of association concerning the authorized share capital of the company.

Dr. Vincent Lawton was re-elected as member and chairman of the board of directors and member of the compensation committee; Dr. Ray Hill was re-elected as member of the board of directors and member of the compensation committee and A Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn and Dr. Isaac Manke were re-elected as members of the board of directors. BDO SA, were elected as the auditors for the 2020 business year and Robert P. Briner, attorney-at-law was re-elected as the independent voting rights representative until the 2021 Annual General Meeting.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »